Emerging multifunctional aspects of cellular serine proteinase inhibitors in tumor progression and tissue regeneration

Pathology International

Volumn 52, Issue 2, 2002, Pages 89-102

  Kataoka, Hiroaki ^a   Itoh, Hiroshi ^a   Koono, Masashi ^a,b  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b Clinical Pathology Laboratory   (Japan)

Author keywords

1 protease inhibitor; Amyloid protein precursor; Hepatocyte growth factor (HGF); HGF activator; HGF activator inhibitor; Kunitz inhibitor; Matrix metalloproteinase; Serine proteinase inhibitor; Serpin

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; AMYLOID PRECURSOR PROTEIN; APROTININ; CELL SURFACE PROTEIN; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 2; MATRIX METALLOPROTEINASE; PLACENTA PROTEIN 5; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEASE NEXIN; SCATTER FACTOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA ANTIGEN; TISSUE FACTOR PATHWAY INHIBITOR 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER INHIBITION; CANCER INVASION; CANCER TISSUE; CARBOXY TERMINAL SEQUENCE; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; TISSUE REGENERATION;

AMINO ACID SEQUENCE; ANIMALS; DISEASE PROGRESSION; HUMANS; MEMBRANE GLYCOPROTEINS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDES; PLANT PROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITORS; TRYPSIN INHIBITORS; TUMOR CELLS, CULTURED; WOUND HEALING;

EID: 0036219009     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2002.01320.x     Document Type: Review

References (132)

1. Proteinase inhibitors in malignancy: Therapeutic promise or another white elephant?
2. Maspin: A tumor suppressing serpin
3. Inhibition of metastasis of Lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models
4. Effects of serine protease inhibitor FOY-305 and heparin on the growth of squamous cell carcinoma
5. 2-macroglobulin in human gastric carcinomas: A retrospective immunohistochemical study
6. Prognostic significance of alpha-1-antitrypsin in early stage of colorectal carcinomas
7. An evaluation of the prognostic significance of alpha-1-antitrypsin expression in adenocarcinomas of the lung: An immunohistochemical analysis
8. Tumor-associated proteases and inhibitors in gastric cancer: Analysis of prognostic impact and individual risk protease patterns
9. Alpha-1-antichymotrypsin expression in lung adenocarcinoma and its possible association with tumor progression
10. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
11. Tumor-associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system
12. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis
13. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors
14. Prognostic significance of urokinase, urokinase receptor and type-1 plasmino-gen activator inhibitor in squamous- and large-cell lung-cancer tissues
15. Expression of the tumor suppressor gene maspin in human pancreatic cancers
16. New human colorectal carcinoma cell lines that secrete proteinase inhibitors in vitro
17. Neutral proteinases and inhibitors secreted by human rectal adenocarcinoma cell line (RCM-1)
18. 1-antitrypsin in vitro
19. Serine proteinase inhibitors produced by various tumor cell lines. Production, relationship to metastatic phenotype and effects on chemotaxis
20. Human colon carcinoma cells synthesize and secrete α1-proteinase inhibitor
21. Enhanced tumor growth and invasivenessin vivo by a carboxyl-terminal fragment of α1-proteinase inhibitor generated by matrix metalloproteinases: A possible modulatory role in natural killer cytotoxicity
22. Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells
23. Squamous cell carcinoma antigen is a new member of the serine protease inhibitor
24. Two apparent human endothelial cell growth factors from human hepatoma cells are tumor-associated proteinase inhibitors
25. Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients
26. Establishment of a new human cancer cell line secreting protease nexin-II/amyloid β protein precursor derived from squamous-cell carcinoma of lung
27. Reverse-zymographic analysis of protease nexin-II/amyloid β protein precursor of human carcinoma cell lines, with special reference to the grade of differentiation and metastatic phenotype
28. Secretion of protease nexin-II/amyloid β protein precursor by human colorectal carcinoma cells and its modulation by cytokines/growth factors and proteinase inhibitors
29. Expression of trypsin in human cancer cell lines and cancer tissues and its tight binding to soluble form of Alzheimer amyloid precursor protein in culture
30. Analysis of tissue factor and tissue factor pathway inhibitor expression in human colorectal carcinoma cell lines and metastatic sublines to the liver
31. Purification and identification of a novel and four known serine protease inhibitors secreted by human glioblastoma cells
32. Increased secretory leukoprotease inhibitor in patients with nonsmall cell lung carcinoma
33. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor
34. Evaluation of hepatocyte growth factor activator inhibitor expression in normal and malignant colonic mucosa
35. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor
36. Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer
37. Conserved expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin in human colorectal carcinomas
38. A SAGE (serial analysis of gene expression) view of breast tumor progression
39. Cell-specific expression of α1-antitrypsin in human intestinal epithelium
40. 1-antitrypsin as a biomarker in azoxymethane induced intestinal tumors in F344 rats
41. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes
42. Invasion-specific genes in malignancy: Serial analysis of gene expression comparisons of primary and passaged cancers
43. 1-antitrypsin secreted by human adenocarcinoma cell lines
44. Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of α 1-antitrypsin
45. Modulation of matrix metalloproteinase-7 (matrilysin) secretion in coculture of human colon carcinoma cells with fibroblasts from orthotopic and ectopic organs
46. 1-Proteinase inhibitor is a neutrophil chemoattractant after proteolytic inactivation by macrophage elastase
47. The serpin-enzyme complex (SEC) receptor mediates the neutrophil chemotactic effect of α-1-antitrypsin-elastase complexes and amyloid-β peptide
48. 2+ in neutrophil-like HL-60 cells: Effect of chemotactic peptide antagonist BocMLF
49. Human monocyte activation by cleaved form of alpha-1-antitrypsin: Involvement of the phagocytic pathway
50. Atherogenic properties of human monocytes induced by the carboxyl terminal proteolytic fragment of alpha-1-antitrypsin
51. Cancer-associated SCM-recognition, immunedefense suppression, and serine protease protection peptide. Part I. Isolation, amino acid sequence, homology, and origin
52. Cancer-associated SCM-recognition, immunedefense suppression, and serine protease protection peptide. Part II. Immunodefense suppressive effects of the CRISPPs peptide
53. Correlation between spontaneous metastatic potential and type I collagenolytic activity in a human pancreatic cancer cell line (SUIT-2) and sublines
54. Changing views of the role of matrix metalloproteinases in metastasis
55. Matrix metalloproteinases. Matrix degradation and more
56. Interstitial collagenase (matrix metalloproteinase-1) expresses serpinase activity
57. 1 antitrypsin by human stromelysin
58. Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3
59. The serpin α1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo
60. Apparent tumor specificity with the SCM test
61. Changes in SCM-responses of lymphocytes in mice after implantation with Ehrlich ascites cells
62. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes
63. The SEC receptor recognizes a pentapeptide neo-domain of α-1-antitrypsin-protease complexes
64. The SEC receptor. A possible link between neonatal hepatitis in α1-antitrypsin deficiency and Alzheimer's disease
65. α1-Antitrypsin is an effector of immunological stasis
66. 1-antitrypsin inhibit natural killing and antibody-dependent cell-mediated cytotoxicity
67. Comparison of the effects of purified human α1-antichymotrypsin and α1-proteinase inhibitor on NK cytotoxicity: Only α1-proteinase inhibitor inhibits natural killing
68. Changes in serum level and affinity for concanavalin A of human α1-proteinase inhibitor in severe burn patients: Relationship to natural killer cell activity
69. Fucosylated forms of alpha-1-antitrypsin that predict unresponsiveness to chemotherapy in ovarian cancer
70. Functional protection by acute phase proteins α1-acid glycoprotein and α1-antitrypsin against ischemia/reperfusion injury by preventing apoptosis and inflammation
71. α1-Proteinase inhibitor, α1-antichymotrypsin, and α2-macroglobulin are the antiapoptotic factors of vascular smooth muscle cells
72. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells
73. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
74. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1
75. 3 binding to vitronectin
76. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin
77. The plasminogen activator inhibitor PAI-1 controlsin vivo tumor vascularization by interaction with proteases, not vitronectin: Implication for antiangiogenic strategies
78. Inhibition of apoptosis in human tumor cells by the tumor-associated serpin, SCC antigen-1
79. Suppression of a squamous cell carcinoma (SCC)-related serpin, SCC antigen, inhibits tumor growth with increased intratumor infiltration of natural killer cells
80. Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives
81. Immunopurification and protease inhibitory properties of protease nexin-2/ amyloid β-protein precursor
82. Secreted form of amyloid β protein precursor is involved in the growth regulation of fibroblasts
83. From differentiation to proliferation: The secretory amyloid precursor protein as a local mediator of growth in thyroid epithelial cells
84. Amino-terminal region of secreted form of amyloid precursor protein stimulates proliferation of neural stem cells
85. A possible role for the Alzheimer amyloid precursor protein in the regulation of epidermal basal cell proliferation
86. Amyloid β protein precursor is involved in the growth of human colon carcinoma cell in vitro andin vivo
87. β-amyloid precursor protein binds to the neurite-promoting IKVAV site of laminin
88. Coagulation factor XIa cleaves the RHDS sequence and abolishes the cell adhesive properties of the amyloid beta protein
89. Down-regulation of the amyloid protein precursor of Alzheimer's disease by antisense oligonucleotides reduces neuronal adhesion to specific substrata
90. Wild-type but not Alzheimer-mutant amyloid precursor protein confers resistance against p53-mediated apoptosis
91. The Alzheimer amyloid precursor protein (APP) and FE65, and APP-binding protein, regulate cell movement
92. β-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity
93. Expression of a ubiquitous, cross-reactive homologue of the mouse β-amyloid precursor protein (APP)
94. Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice
95. Bacterial expression, purification, and functional mapping of the Amyloid β/A4 protein precursor
96. Amino acid sequence RERMS represents the active domain of Amyloid β/A4 protein precursor that promotes fibroblast growth
97. Secreted β-amyloid precursor protein stimulates mitogen-activated protein kinase and enhance τ phosphorylation
98. Phosphorylation of mitogen-activated protein kinase is altered in neuroectodermal cells overexpressing the human amyloid precursor protein 751 isoform
99. Amino-terminal region of the beta-amyloid precursor protein activates mitogen-activated protein kinase
100. Hepatocyte growth factor: A multifunctional cytokine
101. Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration
102. Plasminogen-related growth factor and semaphorin receptors: A gene superfamily controlling invasive growth
103. A novel protease obtained from FBS-containing culture supernatant, that processes single-chain form hepatocyte growth factor to two chain form in serum-free culture
104. Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor
105. Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator
106. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma
107. Pericellular activation of hepatocyte growth factor/scatter factor (HGF/SF) in colorectal carcinomas: Roles of HGF activator (HGFA) and HGFA inhibitor type 1 (HAI-1)
108. Hepatocyte growth factor activator: A possible regulator of morphogenesis during fetal development of the rat gastrointestinal tract
109. Activation of HGF by endogenous HGF activator is required for metanephric kidney morphogenesis in vitro
110. Genomic structure and chromosomal localization of the human hepatocyte growth factor activator inhibitor type 1 and 2 genes
111. Mouse hepatocyte growth factor activator inhibitor type 1 (HAI-1) and type 2 (HAI-2)/placental bikunin genes and their promoters
112. Up-regulation of hepatocyte growth factor activator inhibitor type-1 but not type-2 along with regeneration of intestinal mucosa
113. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment
114. Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues: Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues
115. Localization of hepatocyte growth factor activator inhibitor type 1 in Langhans' cells of human placenta
116. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo
117. Multiple sites of proteolytic cleavage to release soluble forms of hepatocyte growth factor activator inhibitor type 1 from a transmembrane form
118. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk
119. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates
120. Characterization of placental bikunin, a novel human serine protease inhibitor
121. Expression profiling of gastric adenocarcinoma using cDNA array
122. Functional analysis of secreted and transmembrane proteins critical to mouse development
123. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase
124. Secretory leukocyte protease inhibitor: A human saliva protein exhibiting anti-HIV-1 activity in vitro
125. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing
126. Secretory leukoprotease inhibitor augments hepatocyte growth factor production in human lung fibroblasts
127. Inhibition of NFκB activation and augmentation of IκBβ by secretory leukocyte protease inhibitor during lung inflammation
128. Identification and cloning of a novel isoform of mouse secretory leukocyte protease inhibitor, mSLPI-β, overexpressed in murine leukemias and a highly liver metastatic tumor, IMC-HA1 cells
129. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis
130. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor
131. Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion
132. Paradoxical pro-invasive effect of the serine proteinase inhibitor tissue factor pathway inhibitor-2 on human hepatocellular carcinoma cells